ProCE Banner Activity

Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need

Slideset

Download these slides from a live satellite symposium at the San Antonio Breast Cancer Symposium covering strategies for integrating oral SERDs into the management of patients with HR-positive/HER2-negative metastatic breast cancer.

Released: November 13, 2024

Expiration: November 12, 2025

Share

Faculty

Virginia Kaklamani

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Erica L. Mayer

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly